Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
LXRXthis companyLexicon Pharmaceuticals, Inc.	$1.87	-8.21×	3.88×	8.38×	-10.76×	-701.5%	99.4%	-98.2%	-101.1%	-46.8%	-28.7%	-16.3%	0.58×	-0.67×	-5.87×	4.88×	0.0%	2	-6.05	1	D+
BCRXBioCryst Pharmaceuticals, Inc.	$7.62	6.19×	-13.74×	1.87×	5.71×	-1611.4%	97.8%	39.0%	30.2%	-221.4%	105.2%	20.0%	-3.68×	1×	4.32×	2.06×	0.0%	5	-3.69	2	B-
DMACDiaMedica Therapeutics Inc.	$9.82	-11.37×	6.66×	0×	-10.97×	-96.7%	0.0%	0.0%	0.0%	-58.4%	-61.0%	-7.8%	0×	0.47×	0×	11.81×	0.0%	1	37.36	2	C
IONSIonis Pharmaceuticals, Inc.	$28.90	-33.24×	25.88×	13.41×	-52.41×	-292.2%	98.3%	-40.5%	-40.4%	-77.9%	-12.0%	-2.5%	5.35×	-7.89×	-4.22×	3.83×	0.0%	2	0.89	1	D+
MNKDMannKind Corporation	$4.14	283.5×	-33.97×	4.97×	77.45×	-1108.3%	82.5%	11.1%	1.7%	-11.5%	5.8%	0.8%	-9.28×	14.48×	2.81×	1.7×	0.0%	1	-4.55	2	C+
NMRANeumora Therapeutics, Inc. Common Stock	$0.53	-1.23×	2.82×	0×	-0.47×	121.4%	0.0%	0.0%	0.0%	-228.1%	-151.8%	-70.6%	0×	0.78×	-74.92×	5.87×	0.0%	2	-18.15	2	C+
Peer median	—	-1.23×	2.82×	1.87×	-0.47×	-292.2%	82.5%	0.0%	0.0%	-77.9%	-12.0%	-2.5%	0×	0.78×	0×	3.83×	0.0%	2	-3.69	2	—